Evidence map›Paper›PMID 24732334›Full record

ArticleThe Journal of investigative dermatology2014

Indomethacin to the rescue of TRAIL-resistant melanomas.

Rajasekharan Somasundaram, Meenhard Herlyn

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rajasekharan SomasundaramMolecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, USA. Electronic address: shyam@wistar.org.
Meenhard HerlynMolecular and Cellular Oncogenesis Program, Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, USA.
The Wistar Institute · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1M
NCI NIH HHS P01 CA114046
6 · The paper itself

Abstract

Patients with melanomas develop resistance to both conventional- and targeted-therapy drugs. Promising clinical responses with immune checkpoint reagents have resulted in renewed interest in the use of biological therapies, although only subsets of individuals are known to respond to these reagents. Tse et al. now report on the use of indomethacin, an anti-inflammatory drug, to sensitize therapy-resistant melanoma cells.

Indexed as

HumansIndomethacinInhibitor of Apoptosis ProteinsMelanomaReceptors, TNF-Related Apoptosis-Inducing LigandSkin NeoplasmsSurvivinTNF-Related Apoptosis-Inducing LigandBIRC5 protein, humanIndomethacinInhibitor of Apoptosis ProteinsReceptors, TNF-Related Apoptosis-Inducing LigandSurvivinTNF-Related Apoptosis-Inducing LigandTNFRSF10B protein, humanTNFSF10 protein, human

Identifiers

PMID24732334
OpenAlexW2062733514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.